Synartro - dosing of second cohort completed in clinical study of SYN321
Synartro AB announces that it has completed the treatment of the second out of four participant cohorts in its phase 1/2a clinical study of SYN321. The third cohort is to be dosed within the coming weeks.
Synartro’s investigational drug SYN321 is a novel joint injection treatment targeting symptoms of knee osteoarthritis. The purpose of the ongoing phase 1/2a study is to evaluate safety and tolerability, as well as to obtain exploratory efficacy data. The first study participant was dosed on September 1st, 2025 and the study is expected to be completed in the spring of 2026. It is conducted together with partner CTC at Uppsala University Hospital in Sweden.
Eight participants were dosed in the second cohort and a total of fifteen participants have been dosed in the first and second cohorts. The study’s safety review committee has now given the green light to proceed with the third cohort.
For further information, please contact:
Magnus Hurst, CFO & acting CEO. Tel: +46 (0) 760 27 44 27. E-mail: magnus.hurst@synartro.com
About Synartro AB
Synartro is a Swedish life science company developing local injection treatments that provide superior and sustained efficacy without systemic side-effects. This is achieved by combining our proprietary slow-release technology with existing proven drugs. Our lead candidate drug SYN321 is a novel treatment of symptomatic osteoarthritis (OA). A disease that leaves hundreds of millions of patients without adequate pain relief.
In addition to the founders, major shareholders include life science investment company Linc AB.